Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Receivables - Other (2020 - 2023)

Historic Receivables - Other for P3 Health Partners (PIIIW) over the last 3 years, with Q1 2023 value amounting to $4.6 million.

  • P3 Health Partners' Receivables - Other rose 68933.98% to $4.6 million in Q1 2023 from the same period last year, while for Mar 2023 it was $4.6 million, marking a year-over-year increase of 68933.98%. This contributed to the annual value of $6.7 million for FY2022, which is N/A changed from last year.
  • Per P3 Health Partners' latest filing, its Receivables - Other stood at $4.6 million for Q1 2023, which was up 68933.98% from $6.7 million recorded in Q4 2022.
  • Over the past 5 years, P3 Health Partners' Receivables - Other peaked at $6.7 million during Q4 2022, and registered a low of $146117.0 during Q4 2020.
  • Moreover, its 3-year median value for Receivables - Other was $1.7 million (2022), whereas its average is $2.5 million.
  • Within the past 5 years, the most significant YoY rise in P3 Health Partners' Receivables - Other was 68933.98% (2023), while the steepest drop was 68933.98% (2023).
  • Quarter analysis of 3 years shows P3 Health Partners' Receivables - Other stood at $146117.0 in 2020, then surged by 4470.31% to $6.7 million in 2022, then tumbled by 30.52% to $4.6 million in 2023.
  • Its Receivables - Other stands at $4.6 million for Q1 2023, versus $6.7 million for Q4 2022 and $2.7 million for Q3 2022.